Skip to content

Carlos Zarate

3 papers in the library · 166 citations · publishing 2023-2026

Papers

Ketamine for the treatment of major depression: a systematic review and meta-analysis

EClinicalMedicine August 1, 2023 Stevan Nikolin, Anthony Rodgers, Andreas Schwaab et al. 166 citations

A systematic review and meta-analysis of 49 randomized controlled trials with 3,299 participants found that racemic ketamine produced larger reductions in depression severity than esketamine, both immediately after the first dose and during repeated dosing. Higher doses were more effective than lower doses. After the final dose, only racemic ketamine maintained a significant effect; esketamine did not. Dropout rates were similar between treatment and control conditions.

Time-Dependent Effects of Rapid-Acting Antidepressants in iPSC-Derived Neurons from Treatment-Resistant Depression and Healthy Volunteers.

Research square February 12, 2026 Jenessa Johnston, Greg Jones, Shiyong Peng et al.

Rapid-acting antidepressants such as ketamine and psychedelics share common downstream effects on gene expression in human cortical neurons, despite targeting different initial receptors. Using stem cells from people with treatment-resistant depression and healthy volunteers, neurons were treated with several compounds. After 6 and 24 hours, gene activity was highly correlated across all drugs, converging on pathways related to inflammation, mTORC1 signaling, and cell growth. One compound, HNK, increased gene activity in excitatory neurons and decreased it in inhibitory neurons. These gene changes matched protein changes in spinal fluid from people given ketamine, supporting the model's relevance for studying antidepressant mechanisms.

Acute ketamine connectivity changes in patients with major depression

Proceedings on CD-ROM - International Society for Magnetic Resonance in Medicine. Scientific Meeting and Exhibition/Proceedings of the International Society for Magnetic Resonance in Medicine, Scientific Meeting and Exhibition September 16, 2025 Jen Evans, Carlos Zarate

Ketamine, a rapid-acting antidepressant, changes functional connectivity in the brain in ways that correlate with the density of receptors known to be involved in depression. In a double-blind placebo-controlled trial, participants received an infusion of ketamine or placebo while undergoing resting-state fMRI. The resulting connectivity changes matched several receptor types linked to depression. This method may help evaluate how new drugs affect the brain.